Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers

INTRODUCTION: Etrolizumab is a novel, dual-action anti-β7 integrin antibody studied in phase 3 trials in patients with inflammatory bowel disease. An autoinjector (AI) is being developed in parallel to complement the prefilled syringe with needle safety device (PFS-NSD) for subcutaneous (SC) adminis...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Adv Ther
Auteurs principaux: Zhang, Wenhui, Tyrrell, Helen, Ding, Han Ting, Pulley, Jennifer, Boruvka, Audrey, Erickson, Rich, Abouhossein, Mariam, Ravanello, Renato, Tang, Meina Tao
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2021
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107163/
https://ncbi.nlm.nih.gov/pubmed/33778929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-021-01661-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires